___

• [1] I.E. Emmanuel,U. Adamu, E. A. Stephen, Quantitative structure and activity relationship modelling study of anti-HIV-1 RT inhibitors: Genetic function approximation and density functional theory method. Journal computational methods in molecular Designs, 5 (2015) 61-76.
• [2] Di Santo, Inhibiting the HIV integration process: past, present and future. J med chem 51 (2014) 539-566.
• [3] D.S. Ruelas , W.C. Greene , An integrated overview of HIV-1 latency. Cell, Elsevier Inc. 155 (2013) 519-529.
• [4] S. Wang, P. Hortz, M. Schechter, L. Rong, Modelling the slow CD4 + T cell Decline in HIV-infected individuals, PLOS Computational Biology 11 (2015).
• [5] A.E. Shola, M.O. Idris, S. Tukur, A.U Saviour, G.A. Shallangwa, A. Uzairu, Theoretical modelling for investigating some active compounds as potent inhibitors against lung cancer. Journal of Engineering and exact science 5(2019) 0125-0136.
• [6] F. Soualmia, S. Belaidi, N. Tchouar, T. Lanez, Review of computational studies applied in new macrolide antibiotics, Journal of fundamental and applied sciences, 12 (2020) 392-415.
• [7] J.S. Jaworska, M. Comber, C.Auer , C.J.Van Leeuwen, Summary of a workshop on regulatory acceptance of QSARs for human health and environmental endpoints, Environmental Health Perspectives, 111 (2003) 1358–1360.
• [8] G. Liu, R. Luo, X. ZHANG, Y. ZHOU, J. LI, Y. ZHENG, H. Liu, Synthesis and Evaluation of Anti-HIV Activities of Novel 7-Hydroxy-1,3-dioxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-4-carboxylate Derivatives, 4 (2014) 573-580.
• [9] Y. He, C. Y. Liew, N. Sharma, S. K. Woo, Y. T. Chau, C. W. Yap, PaDEL-Descriptor: Open source software for PD-PK-T prediction, Journal of computational chemistry, 34 (2013) 604-610.
• [10] A.E.Shola, S. Uba, A. Uzairu, In Silico Study for investigating and predicting the activities of 1, 2, 4-Tirazole Derivatives as potent Anti-Tubercular agents. The Journal of Engineering and Exact Science 4 (2018) 0246-0254.
• [11] Alexander Tropsha. Best practices for QSAR model Development, validation and exploitation, Molecular Informatics. Inf. 29 (2010) 476-488.
• [12] A. Golbraikh; A Tropsha, Predictive QSAR modeling based on diversity sampling of experimental datasets for the training and test set selection, J Comput Aided Mol Des., 20 (2002) 269–276.
• [13] A. Racz, D. Bajusz, K. Heberger, Intercorrelation limits in molecular descriptors preselection for QSAR/QSPR, Molecular informatics 38 (2019) 1-6.
• [14] K. Roy, J.T. Leonard, On selection of training and test sets for the development of predictive QSAR models. QSAR and Combinatorial Science 25 (2006) 235-251.
• [15] M. Patel, N. Malle Shappa, S. Poonam, J. Varun, B. Sumit, L. Sandeep, A. Vikrant, D. Saurabh, B. Varun, QSAR studies as strategic approach in drug discovery. Med Chem 23 (2014) 4991-5007.
• [16] J.H. Holland, Adaptation in natural and artificial system, University of Michigan Press. (1975).
• [17] V. Ravinchandran, R. Harish, J. Abhishek, S. Shalini, P.V. Christapher, K.A. Ram, Validation of QSAR models-strategies and importance, International Journal of Drug Design and Discovery, 2 (2011) 511-519.
• [18] A.Tropsha, P. Grammatica, V.K. Gombar, The importance of being Earnest: Validation is the Absolute essential for successful Application and interpretation of QSAR models, QSAR and Combinatorial Science 22 (2003) 69-77.
• [19] K. Roy, Some aspects of validation of predictive quantitative structure-activity relationship models, Expert Opinion On Drug Discovery 2 (2007) 1567-1577.
• [20] A.S. Ugochukwu, G. A. Shallangwa, A. Uzairu, Quantitative Structure and Activity Relationship of 3a, 6a – Dihydro-1H-pyrrolo [3,4-c]pyrazole-4,6-dione Derivatives, Turkish Computational and Theoretical Chemistry. 4 (2020) 32-39.